bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer
May 01 2023 - 8:00AM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a
biotechnology company focused on the need for noninvasive, accurate
tests for the detection of early-stage cancer, today announced that
Michael Dougherty has joined the company as Chief Financial
Officer, effective today. Mr. Dougherty is an experienced C-level
executive with more than 20 years in financial management and
business strategy.
Mr. Dougherty will report directly to bioAffinity Technologies
President and Chief Executive Officer Maria Zannes. Former CFO
Michael Edwards will be available as a consultant to ensure a
smooth transition.
“We are delighted to welcome Mike to our executive leadership
team. He brings a tremendous skill set developed in senior
positions at Amazon and Russell Investments. His expertise in
financial management will play an important role in the nationwide
commercial rollout of CyPath® Lung,” Ms. Zannes said. “His
experience in strategy development and M&A will be crucial as
we expand the CyPath® brand into other indications and pursue
therapeutics opportunities. I look forward to his input and
leadership as we increase visibility for our Company among
investors, analysts and the broader financial community.”
Most recently, Mr. Dougherty was Chief Financial Officer of
Alexa Business Domains, Amazon’s Alexa AI and Voice division, where
he was responsible for financial strategy over Alexa’s
multi-billion-dollar investments in AI-generated customer
experiences. Previously, Mr. Dougherty was Chief Financial and
Operating Officer of TINT, a user-generated content platform, and
Chief Financial Officer at Filestack, a secure file handling
service provider that was acquired by Idera, Inc. Prior to that,
Mr. Dougherty served as Chief Financial Officer for Amazon Pay,
where he supported Amazon’s digital payment wallet globally.
Earlier in his career Mr. Dougherty held various finance positions
at Russell Investments and Medisystems Corporation. He is a
certified public accountant and a Chartered Global Management
Accountant by the American Institute of Certified Public
Accountants.
“As a finance executive at both large enterprise business units
and private equity-backed growth firms, my focus has always been on
operational excellence, legal and regulatory compliance, and
stewardship of company resources. I am excited to join bioAffinity
Technologies during this pivotal time in the evolution of its
business,” Mr. Dougherty said. “CyPath® Lung has significant
potential to improve early-stage lung cancer diagnosis and extend
lives. I look forward to leading the financial strategy to support
its expansion and create value for our shareholders.”
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and targeted cancer treatment. The Company’s first product,
CyPath® Lung, is a noninvasive test that has shown high sensitivity
and specificity for the detection of early-stage lung cancer.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by
Precision Pathology Services. OncoSelect® Therapeutics, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio. For more information, visit
www.bioaffinitytech.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005136/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart
From May 2024 to Jun 2024
bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart
From Jun 2023 to Jun 2024